Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors.

@article{Gore2004UpdatedRF,
  title={Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors.},
  author={Lia Gore and Scott N. Holden and Michele L. Basche and S Krishna Raj and Ittamar Arnold and Cindy O'Bryant and Samir E. Witta and Beate Rohde and Candice McCoy and S. Gail Eckhardt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={3026}
}
3026 Background: Inhibition of HDACs in vitro has resulted in tumor cell growth arrest, differentiation and/or tumor apoptosis. This report evaluates the pharmacokinetics (PK) and pharmacodynamics (PD) of MS-275, an orally active synthetic benzamide derivative HDAC inhibitor, and presents updated clinical data from this phase I trial. METHODS MS-275 was given orally to 3-6 fasting patients per dose level with refractory/relapsed solid tumors or lymphoma. The plasma PK profile of MS-275 was… CONTINUE READING